Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

QinetiQ shares rise on defence spending hopes, Berenberg raises target price

(Sharecast News) - Shares in security and defence contractor QinetiQ were rising strongly on Monday on the back of news of increases to defence spending by the UK government, which broker Berenberg said underpins the outlook for the business. In an interview with The Times published this weekend, defence secretary John Healey said there as "no doubt" that UK defence spending would increase to the equivalent of 3% of GDP by 2034.

That follows comments in February from prime minister Keir Starmer that defence spending would rise to 2.5% by April 2027 with an "ambition" to hit 3% by 2034.

The Office for Budget Responsibility has said that meeting the 3% target "would cost an additional £17.3bn in 2029-30".

"This is most positive for QinetiQ in our aerospace and defence coverage as it derives the highest share of revenue - 57% - from the UK Ministry of Defence," Berenberg said in a research note.

"This positive UK backdrop continues to underpin the outlook, and the US outlook is de-risked given the restructuring and the company's decision to focus on four business areas."

Berenberg added that the stock, which it rates a 'buy', still trades at a 25% discount to others in the UK defence sector on a price-to-earnings basis. The broker set a new target price of 570p for the shares, up from 500p previously.

The stock was up 5.2% at 522.79p by 1304 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.